Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Michael White

Showing results (11-20 of 284) with videos related to

Pageof 29
Sort By:
Connecticut Medicine|November 1, 2002
Antipsychotics and QTc interval prolongationC Michael White
Journal of Clinical Pharmacology|September 5, 2002
A review of the pharmacologic and pharmacokinetic aspects of rosuvastatinC Michael White
The Annals of Pharmacotherapy|February 11, 2020
Current System of Overseeing Drug Trials in Developing Countries by the FDA Is DangerousC Michael White
Journal of the American Pharmacists Association : Japha|May 31, 2020
Counterfeit drugs: A major issue for vulnerable citizens throughout the world and in the United StatesC Michael White
Evidence-Based Nursing|May 31, 2019
Nurses must be aware of the potential for causing distress when recruiting vulnerable populations to research projectsC Michael White
The Annals of Pharmacotherapy|March 27, 2018
Reply: Should an LDL Cholesterol Target-Based Approach Be Readopted?C Michael White
American Heart Journal|January 13, 2005
Thrombin-directed inhibitors: pharmacology and clinical useC Michael White
The Annals of Pharmacotherapy|October 2, 2015
Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and AlirocumabC Michael White
Journal of Clinical Pharmacology|May 24, 2018
The Pharmacology, Pharmacokinetics, Efficacy, and Adverse Events Associated With KavaC Michael White
Journal of Cardiovascular Pharmacology and Therapeutics|April 14, 2018
The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of HypercholesterolemiaC Michael White
Pageof 29

Showing results (11-20 of 284) with videos related to

Sort By:
Pageof 29
Connecticut Medicine|November 1, 2002
Antipsychotics and QTc interval prolongationC Michael White
Journal of Clinical Pharmacology|September 5, 2002
A review of the pharmacologic and pharmacokinetic aspects of rosuvastatinC Michael White
The Annals of Pharmacotherapy|February 11, 2020
Current System of Overseeing Drug Trials in Developing Countries by the FDA Is DangerousC Michael White
Journal of the American Pharmacists Association : Japha|May 31, 2020
Counterfeit drugs: A major issue for vulnerable citizens throughout the world and in the United StatesC Michael White
Evidence-Based Nursing|May 31, 2019
Nurses must be aware of the potential for causing distress when recruiting vulnerable populations to research projectsC Michael White
The Annals of Pharmacotherapy|March 27, 2018
Reply: Should an LDL Cholesterol Target-Based Approach Be Readopted?C Michael White
American Heart Journal|January 13, 2005
Thrombin-directed inhibitors: pharmacology and clinical useC Michael White
The Annals of Pharmacotherapy|October 2, 2015
Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and AlirocumabC Michael White
Journal of Clinical Pharmacology|May 24, 2018
The Pharmacology, Pharmacokinetics, Efficacy, and Adverse Events Associated With KavaC Michael White
Journal of Cardiovascular Pharmacology and Therapeutics|April 14, 2018
The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of HypercholesterolemiaC Michael White
Pageof 29